174 results found | searching for "outsourcing"

2 3 4 5 6 7 8 9 10 Next Last 
  • MedResponsive
  • An SEO outsourcing company can help in creating a Google Business Profile, which makes it easier for local customers to find your business easily. https://www.medresponsive.com/blog/how-to-create-a-google-business-profile-page/
  • jameshebrew
  • The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis A number of biopharmaceutical companies are outsourcing their biologics fill / finish operations, thereby, prompting stakeholders engaged in this domain to undertake several expansion initiatives, to cater to the needs of clients around the globe. Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings. Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/256/request-sample.html Key Market Insights More than 175 service providers claim to offer services for biologic fill / finish operations The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide. Several partnerships have been established in the biologics fill / finish services domain, since 2013 Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines. Over 170 expansions have been reported in biologics fill / finish services domain, since 2013 More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations. The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees). The demand for biologics fill / finish services is expected to grow at an annualized rate of 14% Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region. Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035 In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/biologics-fill-finish-services-market/256.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • jameshebrew
  • The mRNA synthesis and manufacturing market is projected to be worth USD 1.5 billion by 2035, claims Roots Analysis Given the current technical and operational challenges associated with the manufacturing of mRNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the mRNA synthesis and contract manufacturing service providers. Roots Analysis has announced the addition of “mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022–2035” report to its list of offerings. Owing to the recent success and growing pipeline of mRNA-based products in the market, mRNA, as a therapeutic agent, has gained significant traction from the medical community. However, due to challenges, such as high capital requirement, stringent regulations and lack of technical expertise, outsourcing has become a preferred business model and CMOs are upgrading their existing capabilities and service portfolios to meet the increased demand for mRNA-based products. Key Market Insights Presently, 30+ companies claim to offer custom synthesis services for mRNA, globally. Majority of the service providers are mid-sized players (44%), followed by small (35%), large (12%) and very large players (9%). Additionally, more than 25% of the stakeholders were established post 2010. It is also worth mentioning that over 50% of the total players are based in North America, specifically in the US. More than 40 companies, across the globe, claim to provide contract manufacturing and fill / finish services for mRNA vaccines / therapeutics. Of the aforementioned players, nearly 85% of the contract manufacturing service providers are based in North America and Europe. Notably, more than 50% of the total players engaged in this space offer services for drug substance (APIs) manufacturing. Currently, more than 95 mRNA synthesis kits are available in the market. Close to 70% of the mRNA synthesis kits contain capping enzymes; of these, 96% use T7 RNA polymerase enzyme mix for the synthesis of modified mRNAs. It is worth highlighting that majority (54%) of the kit developers are small players. More than 170 clinical trials have been registered for the evaluation of mRNA-based therapeutics / vaccines, worldwide. The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 44%, during the period 2017-2022. Of the total number of trials registered, close to 22% have already been completed, while 46% of the studies are actively recruiting participants. Partnership activity within this domain has grown at a CAGR of 60%, between 2019 and 2022. Nearly 34% of the deals were inked in 2021. Majority of the instances captured in the report were manufacturing agreements, representing 22% of the total partnerships. Further, most of the intercontinental deals have been inked by players based in North America. North America and Europe are anticipated to capture close to 65% of the global market share, by 2035. The market in Asia Pacific is likely to grow at the highest CAGR during the period 2022-2035. In terms of type of product, drug substance (APIs) is expected to occupy a larger share (70%) of the overall mRNA synthesis and manufacturing service market in 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market/request-sample.html Key Questions Answered  What are the factors driving mRNA synthesis and manufacturing market?  How many players are providing services for custom synthesis of mRNAs?  How many players are offering mRNA contract manufacturing services for commercial purposes?  How many kits are available in the market for the synthesis of mRNA?  Which geographical segment has the highest growth rate in mRNA synthesis and manufacturing market?  Which segment, in terms of type of product, accounts for the largest mRNA synthesis and manufacturing market share?  What is the partnership and collaboration trends in mRNA synthesis and manufacturing domain?  Who are the key players in mRNA synthesis and manufacturing market? The financial opportunity within the mRNA synthesis and manufacturing service market has been analysed across the following segments:  Type of Product  Drug substances (APIs)  Drug products (FDFs)  Application Area  mRNA-based vaccines  mRNA-based therapeutics  Therapeutic Area  Infectious diseases  Oncological disorders  Other diseases  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa  Rest of the World The research also includes detailed profiles of the key players (listed below) engaged in mRNA synthesis and manufacturing domain; each profile features a brief overview of the company, details related to its service portfolio (for mRNA synthesis and contract manufacturing service providers) / product portfolio (mRNA synthesis kit providers), recent developments and an informed future outlook.  Aldevron  APExBIO  Biomay  Bio-Synthesis  CELLSCRIPT  eTheRNA  Eurogentec  Jena Biosciences  New England Biolabs  Thermo Fisher Scientific  TriLink BioTechnologies For additional details, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • jameshebrew
  • The liposome development and manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis Driven by the development of advanced methods for preparation and characterization of liposomes, and the application of these molecules in therapeutics and diagnostics, the demand for liposomes is expected to rise in the coming years. London Roots Analysis has announced the addition of “Liposome Manufacturing Market, 2022-2035” report to its list of offerings. Despite the growing interest in liposome-based therapeutics and diagnostics, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. In order to deal with the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers. Key Market Insights More than 70 companies are currently offering services related to liposome development and manufacturing, globally Majority (74%) of the service providers offer formulation development services for liposomes. This is followed by players offering analytical method development (65%), liposome contract manufacturing (64%), and process development (61%) services. Close to 6,100 articles focused on liposomes, have been published in reputed scientific journals, since 2017 More than 50% of the articles focused on liposomes were published post-2019. Popular journals that have published multiple articles include International Journal of Pharmaceutics, Journal of Controlled Release, and Pharmaceutics. More than 800 clinical trials have been registered for the evaluation of liposome-based therapeutics, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 17%, during the period 2017-2021. Of the total number of trials registered, 60% have already been completed, while 26% of the studies are actively recruiting participants. Nearly 700 patents related to liposomes have been filed / granted, since 2017 Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 55% of patent applications have been filed post-2016. It is worth noting that 61% patents related to liposomes were filed / granted in the US alone. Over 110 global events related to liposomes were organized in the past couple of years Majority (63%) of the events related to liposomes, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. Further, the agendas of the events organized post-2020 include discussions on the applications, and recent advancements in technologies associated with liposomes. Go / No-Go framework can be used to assist players in the crucial outsourcing decision-making process The framework enables evaluation of the current capabilities of liposome-based therapeutic developers, based on 4+ parameters, including trial phase, target therapeutic area, location of trial(s), patient enrollment and willingness to outsource. North America is anticipated to capture over 40% of the global market share for liposome development and manufacturing services, by 2035 In terms of type of product formulation, the therapeutic formulations of liposomes (71%) are anticipated to capture the highest share, this trend is unlikely to change in the foreseen future. Further, based on end users, majority of the revenue share (76%) of the overall market is likely to be driven by pharmaceutical and biotechnology industry, by 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/liposome-manufacturing-market/request-sample.html Key Questions Answered  Who are the key players offering liposome development and manufacturing services?  What is the evolving trend of publications focused on liposomes?  How many patents, related to liposomes, have been filed / granted in the past few years?  Which companies are actively involved in conducting clinical trials for liposomes?  What are the key agenda items being discussed in various global events / conferences related to liposomes?  Which factors are likely to influence the decision of liposome manufacturing being done in-house or outsourced?  How is the current and future market opportunity related to liposome development and manufacturing services, likely to be distributed across key market segments? The financial opportunity within the liposome development and manufacturing services market has been analyzed across the following segments:  Type of Product Formulation  Therapeutic  Nutraceutical  Scale of Operation  Discovery / Research  Preclinical  Clinical  Commercial  End User  Pharmaceutical and Biotechnology Industry  Cosmetic Industry  Food Industry  Agricultural Industry  Academics  Other Industries  Key Geographical Regions  North America  Europe  Asia-Pacific  Middle East and North Africa  Latin America The research also includes detailed profiles of the key players (listed below) offering services for liposome development and manufacturing; each profile features an overview of the company, its financial information (if available), details on service portfolio, recent developments and an informed future outlook.  Baxter BioPharma Solutions  Charles River Laboratories  Evonik  Fresenius Kabi  Fujifilm  GEA  Intertek For additional details, please visit https://www.rootsanalysis.com/reports/liposome-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Biologics Fill Finish Services Market (3rd Edition), 2022-2035 2. Bioavailability Enhancement Technologies and Services Market, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com [more]
  • vtestcorp
  • Software testing and quality assurance services A reputable software assurance outsourcing company uses standardized testing techniques to always fulfill deadlines on time and quickly adapt to personnel changes. Successful QA testing outsourcing can guarantee that your business can produce a web or mobile applications more quickly and be adaptable when it comes to team changes. Vtestcorp software testing and quality assurance services completely follow those of our clients. Visit www.vtestcorp.com for details. https://www.vtestcorp.com/software-testing-and-quality-assurance-services/ [more]
  • vtestcorp
  • https://justpaste.it/48acj Enterprises Consider QA Outsourcing Services as A Boon Price effectiveness: The bottom line is what counts in the end. It can be expensive to set up an internal QA team and accompanying infrastructure. This is because test engineers must get a salary and other benefits, and new automation technologies must be purchased to help the team. Additionally, when new testing methodologies or technologies gain favor in the market, the QA crew must be taught them. However, outsourcing QA testing services in US might provide specialized skills for a far lower price than building an internal QA staff. [more]
  • latestmarketnews
  • Increased economic activity in various industries has paved way for increased activity across the Business Process Outsourcing (BPO) industry. The industry through its functions contributes to ESG in many ways, specifically contributing positively to the environment and governance aspects through integrating different technologies. The BPO market through its services influences the social aspect of the ESG as it focuses on improving customer relationship management and employs many human resources across different industries. Why is it important to have ESG? The abbreviation ESG stands for environmental, social and corporate governance. It is a measurement that takes into account a company's social and environmental impact on the global community. It brings awareness to the different climate issues that are occurring and encourages businesses to adopt practices and policies that are better for the environment. ESG not only helps businesses by attracting a more diverse workforce to bring in new ideas, but it also helps businesses have a greater positive impact on our world. Read More @ https://astra.grandviewresearch.com/business-process-outsourcing-industry-esg-outlook [more]
  • mtscompany
  • Outsourcing medical transcription to an expert is a feasible strategy to avoid misinterpretation of abbreviations in the EHR. https://bit.ly/3XfBAU8 [more]
  • nikitakalra
  • contactpoint360
  • TOP HEALTHCARE BPO SOLUTIONS: ENHANCING PATIENT OUTCOMES Healthcare Business process outsourcing (BPO) companies in the healthcare industry can help improve patient outcomes in several ways. Organizations can deploy healthcare business BPO solutions to deliver intelligent health operations that improve patient outcomes, keep costs under control, and increase consumer and provider engagement. By outsourcing specific administrative or clinical tasks to a healthcare call center BPO company, a healthcare organization can benefit from the specialized expertise and resources of that company, which can help improve the efficiency and effectiveness of its operations. This can lead to better patient outcomes, cost savings, and increased consumer and provider satisfaction. Additionally, by outsourcing healthcare call center services to a reliable BPO company that uses advanced technologies such as artificial intelligence (AI) and machine learning, a healthcare organization can improve its ability to analyze and interpret data, which can help inform decision-making and drive better patient outcomes. It is essential for a healthcare organization to carefully evaluate potential BPO partners and their capabilities to find the best fit for its needs and goals. ContactPoint 360 helps clients drive breakthrough growth by integrating healthcare call center BPO services and subject matter expertise with analytics, automation, artificial intelligence, and innovative talent. Schedule a meeting with our customer experience expert to get started.
2 3 4 5 6 7 8 9 10 Next Last